Effect of infosheet for topical tacrolimus 0.1% and its efficacy and compliance in the treatment of atopic dermatitis.
10.4168/aard.2013.1.3.221
- Author:
Ji Su HAN
1
;
Woo Jin LEE
;
Joo Yeon KO
;
Joung Soo KIM
;
Sang Seok KIM
;
Soo Hong SEO
;
Bark Lynn LEW
;
Ga Young LEE
;
Ju Hee LEE
;
Chang Ook PARK
;
Sang Jai JANG
;
Hyun Soo PARK
;
Seung Phil HONG
;
Sung Eun CHANG
;
Mi Woo LEE
;
Jee Ho CHOI
;
Kee Chan MOON
;
Chong Hyun WON
Author Information
1. Department of Dermatology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea. chwon98@chol.com
- Publication Type:Original Article
- Keywords:
Atopic dermatitis;
Topical calcineurin inhibitor;
Topical tacrolimus 0.1%;
Information
- MeSH:
Calcineurin;
Compliance;
Dermatitis, Atopic;
Hospitals, General;
Humans;
Immunoglobulin A;
Korea;
Medical Records;
Patient Compliance;
Prostaglandins A;
Tacrolimus
- From:Allergy, Asthma & Respiratory Disease
2013;1(3):221-226
- CountryRepublic of Korea
- Language:Korean
-
Abstract:
PURPOSE: Topical calcineurin inhibitor is recently developed topical immunomodulator, and preliminary studies showed its effectiveness in the treatment of atopic dermatitis (AD). However, some side effects including transient irritation can influence the patient compliance. So, there are some needs to improve the patient compliance. The purpose of this study was to evaluate the efficacy, safety and patient compliance with using topical tacrolimus 0.1% to treat AD when the correct information about topical tacrolimus are properly given to patients. METHODS: We examined the medical recordings, clinical severity scoring of total 194 AD patients at 9 general hospitals in Seoul, Korea from September 2010 to August 2011. We offered an infosheet of topical tacrolimus 0.1% and the patients applied it twice a day for 2 weeks. And we measured the efficacy of the topical tacrolimus 0.1% with SCORing atopic dermatitis (SCORAD) index, patient's global assessment (PGA), and investigator's global assessment (IGA). RESULTS: Topical tacrolimus 0.1% effectively controlled AD with a reduction of the SCORAD index from baseline 31.9 to 20.2 at 2 weeks of application. In IGA results showed 98% got improvement and in PGA, results showed 96% got improvement after treatment. Although 42.3% of the patients complained of adverse effects, these were all transient. The effect of information on topical tacrolimus 0.1% showed 34% patients could predict the side effect, 35% patients could feel safety to use, and 18% patients experienced side effect but could maintain topical calcineurin inhibitor. CONCLUSION: Topical tacrolimus 0.1% may be an effective treatment modality for AD when patients show good compliance for applying the ointment. And properly given, the correct information may increase the patient compliance.
